



## Correction to: Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes

José H. Volders<sup>1</sup> · Vera L. Negenborn<sup>2</sup> · Pauline E. Spronk<sup>3</sup> · Nicole M. A. Krekel<sup>2</sup> · Linda J. Schoonmade<sup>4</sup> · Sybren Meijer<sup>1</sup> · Isabel T. Rubio<sup>5</sup> · M. Petrousjka van den Tol<sup>1</sup>

Published online: 11 January 2018  
© Springer Science+Business Media, LLC, part of Springer Nature 2018

**Correction to: Breast Cancer Research and Treatment**  
<https://doi.org/10.1007/s10549-017-4598-5>

In the original publication of the article, Table 1 was published incorrectly. The corrected Table 1 is given in this erratum. The original article has been corrected.

---

The original article can be found online at <https://doi.org/10.1007/s10549-017-4598-5>.

---

✉ M. Petrousjka van den Tol  
[mp.vandentol@vumc.nl](mailto:mp.vandentol@vumc.nl)

- <sup>1</sup> Department of Surgical Oncology, VU University Medical Center, De Boelelaan 1117, Room 7F-020, 1081 HV Amsterdam, The Netherlands
- <sup>2</sup> Department of Plastic, Reconstructive and Hand Surgery, VU University Medical Center, Amsterdam, The Netherlands
- <sup>3</sup> Dutch Institute for Clinical Auditing, Leiden, The Netherlands
- <sup>4</sup> Medical Library, VU University Amsterdam, Amsterdam, The Netherlands
- <sup>5</sup> Breast Cancer Surgical Unit, Breast Cancer Center, Hospital Universitario Vall d'Hebron, Barcelona, Spain

**Table 1** Margin status and additional therapies

| Study                 | Study type                    | Inclusion period | Comparison  | BCS after NACT (vs primary BCS) | Lobular carcinoma (%) | Definition positive margin   | Positive margins (%)                      | Additional boost (%) | Re-excision (%)            | Secondary mastectomy (%)   | pCR (%) | OCEBM evidence |
|-----------------------|-------------------------------|------------------|---|---------------------------------|-----------------------|------------------------------|---|----------------------|----------------------------|----------------------------|---------|----------------|
| Assersohn (1999) [24] | Randomized controlled trial   | 1990–1995        | NACT 4x plus adjuvant 4x vs 8x adjuvant chemo-therapy | 98 vs 86                        | NR                    | inked margin close < 1 mm    | 40% vs 36%                                | NR                   | 0% vs 0%                   | 0% vs 0%                   | NR      | 3              |
| Boughey (2006) [25]   | Prospective cohort (RCT data) | 1998–2005        | NACT vs adjuvant chemo-therapy                        | 162 (vs 101)                    | NR                    | ≤ 2 mm                       | NR  | NR                   | 12.3% vs 13.9%             | 7.4% vs 9.9%               | NR      | 3              |
| Waljee (2008) [26]    | RSCC                          | 2002–2006        | NACT vs adjuvant chemo-therapy                        | 65 (vs 211)                     | NR                    | NR                           | NR  | NR                   | 31.3% vs 58.8% (p = 0.001) | 14.1% vs 16.7% (p = 0.001) | NR      | 4              |
| Komenaka (2011) [27]  | RSCC                          | 2002–2009        | NACT vs adjuvant chemo-therapy                        | 39 (vs 68)                      | NR                    | Inked margin close < 1 mm    | 23% vs 46% (close or positive) (p = 0.04) | NR                   | 18% vs 41% (p = 0.01)      | 2.6% vs 8.8%               | NR      | 4              |
| Tiezzi (2008) [31]    | RSCC                          | 1990–2003        | NACT vs no NACT                                       | 88 (vs 191)                     | NR                    | ≤ 1 mm                       | 19.3% vs 13.1%                            | NR                   | 0% vs 0%                   | 0% vs 0%                   | NR      | 4              |
| Christy (2009) [29]   | RSCC                          | 2002–2007        | NACT vs no NACT                                       | 31 (vs 62)                      | NR                    | Positive NR close < 1 mm     | 10% vs 32% (p < 0.01)                     | NR                   | 3.2% vs 17.7% (p < 0.01)   | 3.2% vs 21.0% (p < 0.01)   | NR      | 4              |
| Karanlik (2015) [28]  | RSCC                          | 2008–2011        | NACT vs no NACT                                       | 80 (vs 116)                     | NR                    | < 5 mm                       | 5% vs 15.5%* (p = 0.02)                   | NR                   | 3.8% vs 7.8% (p = 0.02)    | 1.3% vs 7.8% (p = 0.02)    | NR      | 4              |
| Volders (2016) [33]   | RSCC                          | 2012–2013        | NACT vs no NACT                                       | 626 (vs 9275)                   | 11.3% vs 9.0%         | Inked margin                 | 27.3% vs 16.4% (p < 0.001)                | NR                   | 4.0% vs 2.3% (p < 0.001)   | 5.1% vs 3.0% (p < 0.001)   | 15%     | 4              |
| Sadetzki (2005) [34]  | RSCC                          | 1995–2001        |   | 100                             | 9%                    | < 5 mm invasive < 10 mm DCIS | NR  | NR                   | 10%                        | 21%                        | NR      | 4              |
| Fukutomi (2006) [35]  | RSCC                          | NR               |   | 113                             | NR                    | NR                           | 24.7%                                     | NR                   | 2nd procedures             | 11.5%                      | NR      | 4              |
| Straver (2010) [36]   | RSCC                          | 2000–2007        |   | 135                             | 15.6%                 | ≤ 2 mm                       | 24%                                       | 15.6%                | 1.5%                       | 6.7%                       | NR      | 4              |

Table 1 (continued)

| Study                 | Study type                      | Inclusion period | Comparison                | BCS after NACT (vs primary BCS) | Lobular carcinoma (%) | Definition positive margin     | Positive margins (%) | Additional boost (%) | Re-excision (%)      | Secondary mastectomy (%) | pCR (%)        | OCEBM evidence |
|-----------------------|---------------------------------|------------------|---------------------------|---------------------------------|-----------------------|--------------------------------|----------------------|----------------------|----------------------|--------------------------|----------------|----------------|
| van Riet (2010) [47]  | RSCC                            | 2003–2008        |                           | 47                              | 6.4%                  | Inked margin                   | 6.4%                 | 2.1%                 |                      | 4.3%                     | 40.4%          | 4              |
| Gobardhan (2012) [38] | RSCC                            | 2009–2010        |                           | 85                              | 6%                    | Inked margin                   | 8.2%                 | 4.8%                 | 0%                   | 3.5%                     | 31%            | 4              |
| Mazouni (2013) [39]   | RSCC                            | 2002–2010        | BCS vs OPBS               | 259; 214 vs 45                  | 6.1% vs 4.4%          | NR                             | 14.1% vs 15.6%       | NR                   | 9% vs 2%             | 18% vs 24%               | 24.3% vs 22.2% | 4              |
| Donker (2013) [40]    | RSCC                            | 2007–2010        | ROLL vs seed localization | 154; 83 vs 71                   | 7% vs 4%              | Inked margin                   | 13% vs 13%           | 6.0% vs 4.2%         | 1% vs 4%             | 6% vs 4%                 | 30% vs 38%     | 4              |
| Gerber (2014) [41]    | Multicenter RCT                 | 2007–2010        | NACT ECDB vs NACT ECD     | 502                             | NR                    | NR                             | 26.5%                | NR                   | 2nd procedures       | 26.5%                    | NR             | 3              |
| Krygh (2014) [30]     | RSCC                            | 2005–2012        | NACT vs no NACT           | 83 vs 1252                      | NR                    | < 5 mm < 2 mm (after Oct 2009) | NR                   | NR                   | 8.8% vs 10.3%        | NR                       | NR             | 4              |
| Ramos (2014) [42]     | Prospective center cohort       | 2008–2012        |                           | 58                              | 5.2%                  | < 2 mm                         | 12.1%                | 0 (0%)               | 6.9%                 | 5.2%                     | 31%            | 4              |
| Amabile (2015) [32]   | RSCC                            | 2009–2013        | NACT vs no NACT           | 44 vs 85                        | 2.3% vs 21.2%         | Positive close < 1 mm          | 27.3% vs 29.4%       | NR                   | 2nd procedures 29.3% | 27.3% vs 29.3%           | 28.1%          | 4              |
| Truin (2016) [43]     | Retrospective national database | 2008–2012        | ILC VS IDC                | 1539; 113 vs 1426               | 100% vs 0%            | NR                             | 33.6% vs 8.6%        | NR                   | 7.1% vs 3.9%         | 26.5% vs 4.7%            | NR             | 4              |
| Rubio (2016) [44]     | Single center cohort            | 2008–2012        | IOUS vs WL                | 214; 145 vs 69                  | 8.3% vs 2.9%          | Inked margin                   | 3.4% vs 4.3%         | NR                   | 8.9% vs 2.9%         | 0.7% vs 5.8%             | 22.7% vs 34.7% | 4              |
| Chauhan (2016) [45]   | Prospective center cohort       | 2012–2014        | BCS vs OPBSTM             | 100; 43 vs 57                   | 2% vs 2%              | Inked margin                   | 8% vs 2%             | NR                   | 2% vs 0              | 5% vs 2%                 | NR             | 4              |

NR not reported, NACT neoadjuvant chemotherapy, ILC invasive lobular carcinoma, IDC invasive ductal carcinoma, IOUS intra operative ultrasound, WL wire guided lumpectomy, BCS breast conserving surgery, OPBS oncoplastic breast surgery, RSCC retrospective single center cohort